Tetrazole-substituted ureas as inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT). A novel preparation of ureas from weakly nucleophilic amines

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 15, 1996, Pages 1753-1758

  Purchase II, Claude F ^a   White, Andrew D ^a   Anderson, Maureen K ^a   Bocan, Thomas M A ^a   Bousley, Richard F ^a   Hamelehle, Katherine L ^a   Homan, Reynold ^a   Krause, Brian R ^a   Lee, Peter ^a   Bak Mueller, Sandra ^a   Speyer, Cecilia ^a   Stanfield, Richard L ^a   Reindel, James F ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 DIMETHYL N (2,4,6 TRIMETHOXYPHENYL)DODECANAMIDE; ACYLTRANSFERASE INHIBITOR; CHOLESTEROL; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME INHIBITION; GUINEA PIG; LIVER; NONHUMAN; RABBIT; RAT;

ANIMALIA; CAVIA PORCELLUS; ORYCTOLAGUS CUNICULUS; SUS SCROFA;

EID: 0030572490     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00310-1     Document Type: Article

References (19)

1. 1. O'Brien, P. M.; Sliskovic, D. R.; Bernabei, A.; Hurley, T.; Anderson, M. K.; Bousley, R. F.; Krause, B. R.; Stanfield, R. L. Bioorg. Med. Chem. Lett. 1995, 5, 295.
2. 2. For recent reviews on ACAT inhibition, see: (a) Krause, B. R.; Bocan, T. M. A. In Inflammation Mediators and Pathways; Ruffolo Jr., R. R.; Hollinger, M. A., Eds.; CRC: New York, 1995, pp 173-197.
3. (b) Roark, W. H.; Roth, B. D. Exp. Opin. Invest. Drugs 1994, 3, 1143.
4. (c) Sliskovic, D. R.; White, A. D. Trends Pharmacol. Sci. 1991, 12, 194.
5. 3. Roth, B. D.; Blankley, C. J.; Hoefle, M. L.; Holmes, A.; Roark, W. H.; Trivedi, B. K.; Essenburg, A. D.; Kieft, K. A.; Krause, B. R.; Stanfield, R. L. J. Med. Chem. 1992, 36, 1662.
6. 50 = 0.11 μM; APCC %ΔTC = -57
7. 50 = 0.024 μM; APCC %ΔTC = -63. See Biological Methods for descriptions of the screens.
8. nd National ACS Meeting; New York, 1991, MEDI 107.
9. 6. Tetrazole 3a is commercially available. Tetrazole 3b can be prepared as previously reported. See (a) Finnegan, W. G.; Henry, R. A.; Lieber, E. J. Org. Chem. 1953, 18, 779.
10. (b) Garbrecht, W. L.; Herbst, R. M. J. Org. Chem. 1953, 18, 1269.
11. 7. Purchase II, C. F.; White, A. D. Syn. Comm. 1996, 26, 2687.
12. 8. For a recent review of the preparation of ureas, see: Sandler, S. R.; Karo, W. In Organic Functional Group Preparations; Wasserman, H. H., Ed.; Academic: New York, 1986; Vol. II, pp 152-191.
13. 25), n-BuLi, THF, -78 °C, 2 h
14. (ii.) isocyanate, warmed to 25 °C and stirred 48 h.
15. 10. Eckert, H.; Forster, B. Angew. Chem. Int. Ed. Engl. 1987, 26, 894.
16. 11. Krause, B. R.; Black, A.; Bousley, R.; Essenburg, A. D.; Cornicelli, J.; Holmes, A.; Homan, R.; Kieft, K. A.; Sekerke, C.; Shaw-Hes, M. K.; Stanfield, R. L.; Trivedi, B. K.; Woolf, T. J. Pharm. Exp. Ther. 1993, 267, 734.
17. 12. Vernetti, L. A.; MacDonald, J. R.; Wolfgang, G. H. I.; Dominick, M. A.; Pegg, D. G. Toxicol. Appl. Pharmacol. 1993, 118, 30.
18. 13. Bocan, T. M. A.; Bak Mueller, S.; Uhlendorf, P. D.; Newton, R. S.; Krause, B. R. Arteriosclerosis Thrombosis 1991, 11, 1830.
19. 14. O'Brien, P. M.; Sliskovic, D. R. Curr. Opin. Therapeut. Pat. 1992, 507.